Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 2

Conditions

Prostatic Neoplasms 4

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 126enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × sulindac sulfone × Genitourinary × Clear all
NCT00283803 2018-08-07

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

University of Washington

Phase 2 Completed
32 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT00052845 2016-07-01

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Alliance for Clinical Trials in Oncology

Phase 2 Completed
80 enrolled
Genitourinary

Prostatic Neoplasms

NCT00078910 2013-06-24

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
130 enrolled
Genitourinary

Prostatic Neoplasms

NCT00166426 2009-11-16

Exisulind Versus Placebo After Surgical Removal of the Prostate

Mayo Clinic

Phase 2 Completed
240 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡